Different Insulin Regimens and Postprandial Coagulation Activation
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study in patients with type 2 diabetes was to investigate the acute effect of postprandial blood glucose levels modified by two different insulin treatment regimens on coagulation activation, inflammation and endothelial cell function. The investigators hypothesized that the rapid-acting insulin analogue aspart has a beneficial postprandial effect on coagulation, endothelial dysfunction and inflammation compared with the intermediate-acting insulin NPH due to its ability to lower postprandial glycaemia.
Condition or disease
Type 2 DiabetesCardiovascular RiskHemostasisInflammationEndothelial Function
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
30 Years to 75 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
age 30-75 years
BMI > 25 kg/m2
type 2 diabetes for more than 4 years
pharmacological anti-diabetic treatment with insulin NPH at bedtime or insulin aspart at meals for more than 24 months
metformin with stable dose >1000 mg/d for more than 12 weeks
acetylsalicylic acid (75 mg/d) for more than 2 weeks
no other anti-diabetic treatment 3 month previously
HbA1c<8.5% at recruitment.
creatinine > 120 µmol/l
ALAT /ASAT > 2.5 x upper reference limit
use of anticoagulants within 1 month previously
any changes in dose of statins within 1 month previously
present or planned pregnancy
mental sickness or alcohol abuse
clinically relevant major organ or systemic illness